Signal from the log
StimCardio
30 M$ · Series A · United States · Medtech
StimCardio met au point Rhyvive, un bracelet qui stimule le nerf médian au poignet pour agir sur le système nerveux autonome et réduire le retour de la fibrillation atriale après une ablation par cathéter. Sa série A, menée par Metis MedTech, finance l'essai pivot NeuroPulse 2.
Article
Announced on , logged by the watch of 29 October 2026.
- Operation
- Funding round
- Announced amount
- 30 M$
- Stage
- Series A
- Country
- United States
- Sector
- Medtech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Metis MedTech , with Catalyst Health Ventures
Provenance
Source prnewswire
Logged on 29 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.